DDInter1594 DDInter899
Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Rilonacept {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Rilonacept {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Rilonacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dactinomycin
Rilonacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Rilonacept {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Rilonacept {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Rilonacept may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Rilonacept may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Dactinomycin
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Rilonacept may lead to a major life threatening interaction when taken with Fingolimod
Rilonacept may lead to a major life threatening interaction when taken with Leflunomide